PUBLISHER: BIS Research | PRODUCT CODE: 1424900
PUBLISHER: BIS Research | PRODUCT CODE: 1424900
Europe Multicancer Screening Market: Analysis and Forecast, 2023-2032
The Europe Multicancer Screening Market Expected to Reach $2.09 Billion by 2032
Introduction to Europe Multicancer Screening Market
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2023 - 2032 |
| 2023 Evaluation | $0.55 Billion |
| 2032 Forecast | $2.09 Billion |
| CAGR | 15.93% |
The Europe multicancer screening market is projected to reach $2.09 billion by 2032 from $0.55 billion in 2023, growing at a CAGR of 15.93% during the forecast period 2023-2032. The multicancer screening market's growth is expected to be propelled by the heightened use of liquid biopsy testing and the escalating prevalence of various cancer types.
Market Introduction
The Europe Multicancer Screening Market is witnessing significant growth due to increasing awareness about early cancer detection and advances in screening technologies. Multicancer screening offers a comprehensive approach to detecting various cancers in their early stages, improving treatment outcomes and reducing mortality rates. Additionally, supportive government initiatives and healthcare policies, along with rising investments in cancer research and screening programs, are driving market expansion. Furthermore, the growing burden of cancer and aging population in Europe accentuates the need for effective screening strategies. With a focus on improving cancer diagnosis rates and enhancing population health, the Europe Multicancer Screening Market is poised for continued growth and innovation, shaping the landscape of cancer care in the region.
Market Segmentation:
Segmentation 1: by Country
- Germany
- France
- U.K.
- Italy
- Spain
- Rest-of-Europe
How can this report add value to an organization?
Growth/Marketing Strategy: The key components in Europe multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.
Competitive Strategy: The key players in the Europe multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Europe multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Table of Contents
Executive Summary
1 Markets
- 1.1 Market Scope
- 1.1.1 Key Questions Answered in the Report
- 1.2 Research Methodology
- 1.2.1 Multicancer Screening Market: Research Methodology
- 1.2.2 Data Sources
- 1.2.3 Market Estimation Model
- 1.2.4 Criteria for Company Profiling
2 Market Overview
- 2.1 Market Overview
- 2.2 Multicancer Screening Workflow Analysis
- 2.3 Market Footprint and Growth Potential
- 2.4 Future Potential
- 2.5 COVID-19 Impact on the Market
3 Industry Insights
- 3.1 Patent Analysis
- 3.1.1 Patent Filing Trend
- 3.1.2 Patent Analysis (by Country)
- 3.1.3 Patent Analysis (by Region)
- 3.2 Reimbursement Scenario
- 3.3 Supply Chain Analysis
- 3.4 Pricing Analysis (by Test Type)
4 Market Dynamics
- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
- 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
- 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
- 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
- 4.4 Market Challenges
- 4.4.1 Lack of Awareness about the Multicancer Screening Tests
- 4.4.2 Too Costly to be Used as Preventive Care
- 4.5 Market Opportunities
- 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
- 4.5.2 New Biomarkers being Discovered Regularly
5 Multicancer Screening Regional Market, 2021-2032
- 5.1 Overview
- 5.2 Europe
- 5.2.1 Germany
- 5.2.2 France
- 5.2.3 U.K.
- 5.2.4 Italy
- 5.2.5 Spain
- 5.2.6 Rest-of-Europe
6 Company Profiles
- 6.1 Overview
- 6.2 Market Value Chain of Multicancer Screening Market
- 6.3 Multicancer Screening Ecosystem Active Players
- 6.4 F. Hoffmann-La Roche Ltd
- 6.4.1 Company Overview
- 6.4.2 Role of F. Hoffmann-La Roche Ltd in the Multicancer Screening Market
- 6.4.3 Key Competitors of the Company
- 6.4.4 Financials
- 6.4.5 Corporate Strategies
- 6.4.6 Business Strategies
- 6.4.7 Analyst Perspective
List of Figures
- Figure 1: Europe Multicancer Screening Market, $Billion, 2022 and 2032
- Figure 2: Share of Multicancer Screening Market (by Region), 2022
- Figure 3: Multicancer Screening Market: Research Methodology
- Figure 4: Primary Research Methodology
- Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 6: Top-Down Approach (Segment-Wise Analysis)
- Figure 7: Multicancer Screening Workflow, End User Perspective
- Figure 8: Multicancer Screening Workflow, Laboratory Technician Perspective
- Figure 9: Europe Multicancer Screening Market, $Billion, 2021-2032
- Figure 10: COVID-19 Impact
- Figure 11: Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
- Figure 12: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
- Figure 13: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
- Figure 14: Supply Chain Analysis of the Multicancer Screening Market
- Figure 15: Multicancer Screening Market Dynamics
- Figure 16: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
- Figure 17: Liquid Biopsy vs. Tissue Biopsy
- Figure 18: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
- Figure 19: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
- Figure 20: Lead-Time Bias in Cancer Screening
- Figure 21: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
- Figure 22: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
- Figure 23: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
- Figure 24: Multicancer Screening Market (by Region), $Billion, 2021-2032
- Figure 25: Europe Multicancer Screening Market, $Billion, 2021-2032
- Figure 26: Europe Multicancer Screening Market (by Country), $Million, 2021-2032
- Figure 27: Germany Multicancer Screening Market, $Million, 2021-2032
- Figure 28: France Multicancer Screening Market, $Million, 2021-2032
- Figure 29: U.K. Multicancer Screening Market, $Million, 2021-2032
- Figure 30: Italy Multicancer Screening Market, $Million, 2021-2032
- Figure 31: Spain Multicancer Screening Market, $Million, 2021-2032
- Figure 32: Rest-of-Europe Multicancer Screening Market, $Million, 2021-2032
- Figure 33: Multicancer Screening Market, Total Number of Companies Profiled
- Figure 34: Multicancer Screening Market: Value Chain
- Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
- Figure 37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
- Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
List of Tables
- Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Multicancer Screening Market
- Table 2: Technological Trends in Multicancer Screening Market
- Table 3: Average Prices of Multicancer Screening Kits Calculation
- Table 4: Likert Scale
- Table 5: Impact Analysis of Market Drivers
- Table 6: Impact Analysis of Market Challenges
- Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
- Table 8: Top Multicancer Screening Tests and Their Costs ($)
- Table 9: Multicancer Screening Market, Pipeline Tests
- Table 10: Cancers and Their Most Common Biomarker Tests
